研究关注：Deepcure develops new BRD4 BD2 inhibitors

## 事件概览

Deepcure Inc. has synthesized new 3,4-dihydroquinoxalin-2(1 H )-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhi...

## 核心信息

Deepcure Inc. has synthesized new 3,4-dihydroquinoxalin-2(1 H )-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors. As such, they are described as potentially useful for the treatment of autoimmune, cardiovascular disease, inflammatory disorders, multiple sclerosis, psoriasis, gout, obesity, and sepsis, among others.

## 为什么值得关注

这条内容与 cell biology 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 51 分的候选评分。

## 发布提示

发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。